miR-29a-3p promotes migration and invasion in ameloblastoma via Wnt/β-catenin signaling by targeting catenin beta interacting protein 1
- PMID: 34636093
- DOI: 10.1002/hed.26888
miR-29a-3p promotes migration and invasion in ameloblastoma via Wnt/β-catenin signaling by targeting catenin beta interacting protein 1
Abstract
Background: Ameloblastoma (AB) is a common epithelial odontogenic tumor. The Wnt/β-catenin pathway has been found to be related to AB invasion.
Methods: The alteration expression of microRNAs (miRNAs) and messenger RNAs (mRNAs) was performed by miRNA and mRNA microarray analysis and validated by quantitative real-time polymerase chain reaction (RT-PCR). The effects of miR-29a-3p on migration and invasion in AB cells were evaluated by a transwell assay. Bioinformatic prediction was conducted using the miRSystem and validated by quantitative RT-PCR, western blot, and a luciferase reporter assay.
Results: miR-29a-3p was overexpressed in AB tissues, which promoted the migration and invasion of AB cells in vitro. Catenin beta interacting protein 1 (CTNNBIP1), a negative regulator of the Wnt/β-catenin pathway, was predicted to be a target of miR-29a-3p. miR-29a-3p inhibited the expression of CTNNBIP1 and promoted the expression of the downstream molecules of the Wnt/β-catenin pathway.
Conclusions: miR-29a-3p promoted migration and invasion in AB via Wnt/β-catenin signaling by targeting CTNNBIP1.
Keywords: Wnt/β-catenin signaling; ameloblastoma; catenin beta interacting protein 1; invasion; miR-29a-3p.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma.Onco Targets Ther. 2024 Aug 6;17:643-653. doi: 10.2147/OTT.S474038. eCollection 2024. Onco Targets Ther. 2024. PMID: 39131904 Free PMC article. Review.
-
Regulation of NEAT1/miR-214-3p on the growth, migration and invasion of endometrial carcinoma cells.Arch Gynecol Obstet. 2017 Jun;295(6):1469-1475. doi: 10.1007/s00404-017-4365-1. Epub 2017 Apr 26. Arch Gynecol Obstet. 2017. PMID: 28447190
-
LncRNA NCK1-AS1 exerts oncogenic property in gastric cancer by targeting the miR-22-3p/BCL9 axis to activate the Wnt/β-catenin signaling.Environ Toxicol. 2021 Aug;36(8):1640-1653. doi: 10.1002/tox.23160. Epub 2021 May 11. Environ Toxicol. 2021. PMID: 33974352
-
Downregulation of lncRNA HOTTIP Suppresses the Proliferation, Migration, and Invasion of Oral Tongue Squamous Cell Carcinoma by Regulation of HMGA2-Mediated Wnt/β-Catenin Pathway.Cancer Biother Radiopharm. 2020 Nov;35(9):720-730. doi: 10.1089/cbr.2019.3017. Epub 2020 Jan 8. Cancer Biother Radiopharm. 2020. PMID: 31910357
-
[Molecular basis of ameloblastoma pathogenesis: A review].Rev Cient Odontol (Lima). 2024 Sep 17;12(3):e212. doi: 10.21142/2523-2754-1203-2024-212. eCollection 2024 Jul-Sep. Rev Cient Odontol (Lima). 2024. PMID: 39444727 Free PMC article. Review. Spanish.
Cited by
-
CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology.J Transl Med. 2024 Jan 12;22(1):50. doi: 10.1186/s12967-023-04680-9. J Transl Med. 2024. PMID: 38216965 Free PMC article. Review.
-
Function and Therapeutic Potential of Non-Coding RNA in Ameloblastoma.Onco Targets Ther. 2024 Aug 6;17:643-653. doi: 10.2147/OTT.S474038. eCollection 2024. Onco Targets Ther. 2024. PMID: 39131904 Free PMC article. Review.
-
Wnt signaling aberrant activation drives ameloblastoma invasion and recurrence: bioinformatics and in vitro insights.BMC Oral Health. 2024 Nov 21;24(1):1421. doi: 10.1186/s12903-024-05003-0. BMC Oral Health. 2024. PMID: 39574093 Free PMC article.
-
MiR-29a-3p inhibits fibrosis of diabetic kidney disease in diabetic mice via downregulation of DNA methyl transferase 3A and 3B.World J Diabetes. 2025 Apr 15;16(4):93630. doi: 10.4239/wjd.v16.i4.93630. World J Diabetes. 2025. PMID: 40236856 Free PMC article.
-
Ameloblastoma: An Updated Narrative Review of an Enigmatic Tumor.Cureus. 2022 Aug 6;14(8):e27734. doi: 10.7759/cureus.27734. eCollection 2022 Aug. Cureus. 2022. PMID: 36127985 Free PMC article. Review.
References
REFERENCES
-
- Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Dis. 2018;24(3):307-316. https://doi.org/10.1111/odi.12646
-
- Kreppel M, Zoller J. Ameloblastoma-clinical, radiological, and therapeutic findings. Oral Dis. 2018;24(1-2):63-66. https://doi.org/10.1111/odi.12702
-
- Nagatsuka H, Han PP, Tsujigiwa H, et al. Heparanase gene and protein expression in ameloblastoma: possible role in local invasion of tumor cells. Oral Oncol. 2005;41(5):542-548. https://doi.org/10.1016/j.oraloncology.2005.01.004
-
- Barberán-Soler S, Vo JM, Hogans RE, Dallas A, Johnston BH, Kazakov SA. Decreasing miRNA sequencing bias using a single adapter and circularization approach. Genome Biol. 2018;19(1):105. https://doi.org/10.1186/s13059-018-1488-z
-
- Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203-222. https://doi.org/10.1038/nrd.2016.246
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials